RxDoctor Payments Data

Mark Lipham, MD

Internal Medicine · Carrollton, GANPI 1437192697

Payments from drug & device makers

$526in general payments, 2019–2025

Across 31 payments — averaging $16.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$188
  • AstraZeneca$169
  • Avanir Pharmaceuticals, Inc.$76
  • Smith+Nephew$37
  • Lilly USA, LLC$20
  • Otsuka America Pharmaceutical, Inc.$20
  • plus $16 from 2 others

What the payments were for

  • Food & beverage$524100%
  • Education$30%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$526 in reported general payments places this provider in the 55th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$130,859
Medicare patients
497
Services billed
1,989

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,072$309,660
AustedoDeutetrabenazine22$195,791
Trelegy ElliptaFluticasone/Umeclidin/Vilanter163$105,118
JanuviaSitagliptin Phosphate190$59,931
XifaxanRifaximin31$57,678
MounjaroTirzepatide46$50,577
TrulicityDulaglutide50$50,439
JardianceEmpagliflozin155$37,411
BelsomraSuvorexant138$36,186
MyrbetriqMirabegron121$32,919
OzempicSemaglutide24$32,399
Combivent RespimatIpratropium/Albuterol Sulfate30$23,738
GemtesaVibegron57$21,365
LinzessLinaclotide38$18,200
FarxigaDapagliflozin Propanediol28$16,546

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$188$115,376187 claims
Lilly USA, LLCMounjaro, Trulicity$20$101,01696 claims
AstraZenecaFarxiga, Brilinta$169$25,87259 claims
Otsuka America Pharmaceutical, Inc.Rexulti$20$14,84928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Carrollton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →